HF 1038 allocates funds from Iowa's opioid settlement to state agencies addressing the opioid crisis, directly affecting programs that provide treatment, prevention, and recovery services. The bill specifies how the money is distributed (disbursed) to eligible state entities and includes rules for when the funding takes effect, including retroactive application for prior periods. It does not change eligibility for the settlement funds but establishes the legal framework for their use. The bill passed unanimously and was signed into law by the Governor on June 6, 2025.
HF 383 would remove the pharmaceutical form of psilocybin (specifically crystalline polymorph COMP 360) from Iowa's Schedule I controlled substances list once the U.S. Food and Drug Administration (FDA) approves it and reschedules it under federal law. This would allow doctors to legally prescribe, distribute, and market COMP 360 for medical use, directly affecting healthcare providers and patients seeking this treatment. The bill automatically aligns Iowa law with federal FDA decisions on this specific pharmaceutical formulation. Note: The bill was vetoed by the governor on June 11, 2025, so it has not become law.
HF 310 strengthens penalties for assaults targeting specific professionals, including healthcare providers. The bill makes existing assault penalties applicable when attacks occur against individuals working in certain occupations, such as healthcare. It directly affects individuals in these professions by ensuring assaults against them face the same legal consequences as other violent crimes. The key provision clarifies that penalties for assaulting these workers will be enforced without additional modifications to existing law.
HF 933 establishes requirements for pediatric palliative care centers in Minnesota, directly affecting children with serious illnesses and their families. The bill mandates specific standards for facility operations, staffing, and care coordination to ensure specialized medical support. It requires centers to meet these standards to provide services for pediatric patients facing life-threatening conditions. Signed into law by the Governor on May 27, 2025, the bill creates a framework for consistent, high-quality palliative care access.
HF 303 modifies rules for insurance company approvals (prior authorization) and the organizations that review medical treatment requests (utilization review organizations). It directly affects healthcare providers, insurers, and patients by changing how prior authorization requests are processed. The bill establishes specific timeframes for reviews and requires utilization review organizations to follow standardized procedures. This aims to reduce delays in patient care while maintaining oversight of treatment appropriateness. The legislation passed unanimously and was signed into law by the Governor on May 27, 2025.
HF 300 creates a multi-state agreement (compact) allowing physician assistants licensed in one participating state to practice in other compact states without needing separate licenses. It directly affects physician assistants seeking to work across state lines and healthcare facilities in participating states. The key provision establishes a standardized licensing process where a license issued by one compact state is recognized by all others in the agreement. This reduces administrative barriers for physician assistants and expands their ability to provide care in multiple states without reapplying for licenses. The bill was signed into law by the Governor on May 27, 2025.
SF 565 provides for the continuation of health insurance coverage for the surviving spouses and children of employees of the state of Iowa. This bill ensures that these family members can maintain their health insurance benefits under specific conditions after the employee's death. It also includes provisions for retroactive applicability, meaning it could apply to past situations. The aim is to offer continued health coverage to these surviving families.
This bill expands Iowa's "Right to Try" Act by broadening the definition of an "eligible patient." Previously limited to individuals with terminal illnesses, the bill now includes patients with life-threatening or severely debilitating illnesses. These patients can access "individualized investigational treatments," which are drugs or products unique to their genetic profile and have successfully completed Phase 1 clinical trials. The bill also defines "eligible facilities" and updates the specific requirements for written informed consent for patients with terminal illnesses.
This bill updates state law by expanding the definition of a "peer review committee." It specifically includes statewide nonprofit organ procurement organizations (OPOs) within this definition. This change grants OPOs the same legal status and protections typically afforded to other peer review committees, such as those in hospitals or medical societies. The bill directly affects organ procurement organizations operating in the state by formally recognizing their internal review processes under this designation.
SF 315, known as the "Iowa Competitive Pharmacy Benefits Managers Marketplace Act," aims to reduce prescription drug costs for public employees in self-funded state health plans. The bill mandates that the state department procure pharmacy benefits manager (PBM) services through a "reverse auction" process. This online, competitive bidding system allows PBMs to offer progressively lower prices for their services. Additionally, the department must acquire a technology platform to conduct these auctions and perform detailed, line-by-line audits of PBM claims to ensure contract compliance. The first PBM contract awarded through this new system is scheduled to take effect on January 1, 2026.
